{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:34:27Z","timestamp":1782830067621,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vancomycin and piperacillin-tazobactam are 2 of the most commonly prescribed antibiotics in hospitals. Recent data from multiple meta-analyses suggest that the combination increases the risk for vancomycin-induced kidney injury when compared to alternative viable options. However, these studies are unable to prove biologic plausibility and causality as randomized controlled trials have not been performed. Furthermore, these studies define acute kidney injury according to thresholds of serum creatinine rise. Serum creatinine is not a direct indicator of renal injury, rather a surrogate of glomerular function. More reliable, specific, and sensitive biomarkers are needed to truly define if there is a causal relationship with increased toxicity when piperacillin-tazobactam is added to vancomycin. This viewpoint will explore the available evidence for and against increased acute kidney injury in the setting of vancomycin and piperacillin-tazobactam coadministration.<\/jats:p>","DOI":"10.1093\/cid\/ciz1189","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T07:11:21Z","timestamp":1576134681000},"page":"426-432","source":"Crossref","is-referenced-by-count":51,"title":["Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-6455","authenticated-orcid":false,"given":"Sean N","family":"Avedissian","sequence":"first","affiliation":[{"name":"Antiviral Pharmacology Laboratory, Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska, USA"},{"name":"College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-0048","authenticated-orcid":false,"given":"Gwendolyn M","family":"Pais","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-2098","authenticated-orcid":false,"given":"Jiajun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5434","authenticated-orcid":false,"given":"Nathaniel J","family":"Rhodes","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-6130","authenticated-orcid":false,"given":"Marc H","family":"Scheetz","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"},{"name":"Pharmacometrics Center of Excellence, Chicago College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"2020071109150083800_CIT0001","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0002","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s11255-018-1870-5","article-title":"Acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam administration: a systematic review and meta-analysis","volume":"50","author":"Chen","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"2020071109150083800_CIT0003","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","author":"Giuliano","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2020071109150083800_CIT0004","first-page":"666","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"2020071109150083800_CIT0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1574886311666161024164859","article-title":"Does piperacillin-tazobactam increase the risk of nephrotoxicity when used with vancomycin: a meta-analysis of observational trials","volume":"12","author":"Mellen","year":"2017","journal-title":"Curr Drug Saf"},{"key":"2020071109150083800_CIT0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamapediatrics.2018.0038","article-title":"The cost of vancomycin and piperacillin\/tazobactam treatment\u2014reply","volume":"172","author":"Downes","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2020071109150083800_CIT0008","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/cid\/cix675","article-title":"Increasing evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy\u2014what is the clinician to do?","volume":"65","author":"Watkins","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2010111124","article-title":"Imperfect gold standards for kidney injury biomarker evaluation","volume":"23","author":"Waikar","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020071109150083800_CIT0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1060028018757497","article-title":"Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: a prospective, multicenter study","volume":"52","author":"Mullins","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2020071109150083800_CIT0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0897190016628960","article-title":"Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin","volume":"30","author":"Peyko","year":"2017","journal-title":"J Pharm Pract"},{"key":"2020071109150083800_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00264-18","article-title":"Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin","volume":"62","author":"Rutter","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109150083800_CIT0013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijantimicag.2017.02.023","article-title":"Acute kidney injury risk associated with piperacillin\/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function","volume":"50","author":"Jeon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2020071109150083800_CIT0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0015","first-page":"1520","article-title":"Vancomycin\/piperacillin-tazobactam nephrotoxicity in the critically ill","volume":"70","author":"Kollef","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0016","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of anti-pseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier","year":"2019;","journal-title":"Clin Infect Dis"},{"key":"2020071109150083800_CIT0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12982-015-0037-4","article-title":"Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology","volume":"12","author":"Fedak","year":"2015","journal-title":"Emerg Themes Epidemiol"},{"key":"2020071109150083800_CIT0018","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2020071109150083800_CIT0019","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jac\/dkz167","article-title":"Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model","volume":"74","author":"Avedissian","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020071109150083800_CIT0020","doi-asserted-by":"crossref","first-page":"e00416-17","DOI":"10.1128\/AAC.00416-17","article-title":"24-hour pharmacokinetic relationships for vancomycin and novel urinary biomarkers of acute kidney injury","volume":"61","author":"O\u2019Donnell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109150083800_CIT0021","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/AAC.00591-16","article-title":"Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin-treated rats","volume":"60","author":"Rhodes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109150083800_CIT0022","article-title":"Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model","author":"Pais","year":"568907. :10.1101\/568907","journal-title":"BioRxiv"},{"key":"2020071109150083800_CIT0023","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40264-019-00846-x","article-title":"Evaluating renal stress using pharmacokinetic urinary biomarker data in critically ill patients receiving vancomycin and\/or piperacillin-tazobactam: a secondary analysis of the multicenter Sapphire study","volume":"42","author":"Kane-Gill","year":"2019","journal-title":"Drug Saf"},{"key":"2020071109150083800_CIT0024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","article-title":"CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial","volume":"17","author":"Tong","year":"2016","journal-title":"Trials"},{"key":"2020071109150083800_CIT0025","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIR.0000000000000312","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"133","author":"Halperin","year":"2016","journal-title":"Circulation"},{"key":"2020071109150083800_CIT0026","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2020071109150083800_CIT0027","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2020071109150083800_CIT0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0272-2712(18)30459-1","article-title":"Assessment of renal function\u2013glomerular and tubular","volume":"13","author":"Duarte","year":"1993","journal-title":"Clin Lab Med"},{"key":"2020071109150083800_CIT0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1464-410X.1985.tb06340.x","article-title":"The effect of trimethoprim on serum creatinine","volume":"57","author":"Kastrup","year":"1985","journal-title":"Br J Urol"},{"key":"2020071109150083800_CIT0030","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1128\/AAC.41.11.2466","article-title":"Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions","volume":"41","author":"Naderer","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109150083800_CIT0031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/34.4.555","article-title":"Inhibition of the renal excretion of tazobactam by piperacillin","volume":"34","author":"Komuro","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2020071109150083800_CIT0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int J Pharm"},{"key":"2020071109150083800_CIT0033","doi-asserted-by":"crossref","first-page":"F1293","DOI":"10.1152\/ajprenal.00013.2012","article-title":"A role for the organic anion transporter OAT3 in renal creatinine secretion in mice","volume":"302","author":"Vallon","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020071109150083800_CIT0034","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.toxlet.2018.06.1220","article-title":"JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats","volume":"295","author":"Wen","year":"2018","journal-title":"Toxicol Lett"},{"key":"2020071109150083800_CIT0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","article-title":"Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat","volume":"86","author":"Lepist","year":"2014","journal-title":"Kidney Int"},{"key":"2020071109150083800_CIT0036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00079-19","article-title":"Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury","volume":"63","author":"Pais","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071109150083800_CIT0037","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2020071109150083800_CIT0038","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2020071109150083800_CIT0039","article-title":"PULMCrit Blog. PulmCrit Wee: is piperacillin-tazobactam nephrotoxic?","author":"Farkas"},{"key":"2020071109150083800_CIT0040","doi-asserted-by":"crossref","first-page":"e000635","DOI":"10.1136\/bmjopen-2011-000635","article-title":"Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial","volume":"2","author":"Jensen","year":"2012","journal-title":"BMJ Open"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1189\/32629869\/ciz1189.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/2\/426\/33486147\/ciz1189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/2\/426\/33486147\/ciz1189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T09:15:46Z","timestamp":1594458946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/2\/426\/5675135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,13]]},"published-print":{"date-parts":[[2020,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1189","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737079076.793587620","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,15]]},"published":{"date-parts":[[2019,12,13]]}}}